egfr tyrosine kinase inhibitors in lung cancer: make no assumptions

Por Melosky†, B.
Publicado em 2012

Supportive care treatments for toxicities of anti-egfr and other targeted agents

Por Melosky, B.
Publicado em 2012

Advanced typical and atypical carcinoid tumours of the lung: management recommendations

Por Melosky, B.
Publicado no Curr Oncol (2018)

Rapidly changing treatment algorithms for metastatic nonsquamous non-small-cell lung cancer

Por Melosky, B.
Publicado no Curr Oncol (2018)

Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer

Por Melosky, B.L.
Publicado em 2008

Response to second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer: make no assumptions

Por Karam, I., Melosky, B.
Publicado em 2012

Optimism about breakthroughs in the age of targeted therapy: the Canadian Lung Cancer Conference 2014; Vancouver, British Columbia; February 7, 2014

Por Melosky, B., Ho, C.
Publicado em 2014

The Canadian Lung Cancer Conference 2016

Por Melosky, B., Ho, C.
Publicado no Curr Oncol (2016)

The changing landscape of thoracic malignancies

Por Melosky, B., Hirsh, V.
Publicado no Curr Oncol (2018)

Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib

Por Melosky, B., Agulnik, J., Assi, H.
Publicado em 2008

Canadian Lung Cancer Conference 2017

Por Chooback, N., Melosky, B., Ho, C.
Publicado no Curr Oncol (2017)

Canadian Lung Cancer Conference 2018

Por Lau, S., Wang, Y., Ho, C., Melosky, B.
Publicado no Curr Oncol (2018)

Canadian supportive care recommendations for the management of anemia in patients with cancer

Por Mikhael, J., Melosky, B., Cripps, C., Rayson, D., Kouroukis, C.T.
Publicado em 2007

A personalized approach to treatment: use of egfr tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada

Por Hirsh, V., Melosky, B., Goss, G., Morris, D., Morzycki, W.
Publicado em 2012

Corrigendum: A personalized approach to treatment: use of egfr tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada

Por Hirsh, V., Melosky, B., Goss, G., Morris, D., Morzycki, W.
Publicado em 2012

Management of skin rash during egfr-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations

Por Melosky, B., Burkes, R., Rayson, D., Alcindor, T., Shear, N., Lacouture, M.
Publicado em 2009

Management of egfr tki–induced dermatologic adverse events

Por Melosky, B., Leighl, N.B., Rothenstein, J., Sangha, R., Stewart, D., Papp, K.
Publicado no Curr Oncol (2015)

Evidence-based best practices for EGFR T790M testing in lung cancer in Canada

Por Stockley, T., Souza, C.A., Cheema, P.K., Melosky, B., Kamel-Reid, S., Tsao, M.S., Spatz, A., Karsan, A.
Publicado no Curr Oncol (2018)

Treatment patterns and survival in patients with ALK-positive non-small-cell lung cancer: a Canadian retrospective study

Por Kayaniyil, S., Hurry, M., Wilson, J., Wheatley-Price, P., Melosky, B., Rothenstein, J., Cohen, V., Koch, C., Zhang, J., Osenenko, K., Liu, G.
Publicado no Curr Oncol (2016)

Standardizing biomarker testing for Canadian patients with advanced lung cancer

Por Melosky, B., Blais, N., Cheema, P., Couture, C., Juergens, R., Kamel-Reid, S., Tsao, M.-S., Wheatley-Price, P., Xu, Z., Ionescu, D.N.
Publicado no Curr Oncol (2018)